Patient characteristics by paraprotein class
. | Paraprotein class, no. (%) . | . | . | . | . | ||
|---|---|---|---|---|---|---|---|
| Factor and grouping . | IgG . | IgA . | LCO . | χ2 . | P . | ||
| General characteristics | |||||||
| Sex | 4.52 | .15 | |||||
| Male | 880 (58) | 413 (58) | 188 (52) | ||||
| Female | 632 (42) | 305 (42) | 173 (48) | ||||
| Age, y | 16.88 | .001 | |||||
| Under 65 | 744 (49) | 334 (47) | 215 (60) | ||||
| 65 or more | 767 (51) | 383 (53) | 146 (40) | ||||
| Performance status | 26.68 | .001 | |||||
| Asymptomatic | 193 (14) | 69 (10) | 19 (6) | ||||
| Minimal symptoms | 516 (37) | 257 (38) | 111 (33) | ||||
| Restricted activity | 544 (39) | 273 (41) | 166 (49) | ||||
| Bedridden | 151 (11) | 69 (10) | 41 (12) | ||||
| Serum albumin, g/L | 149.03 | < .001 | |||||
| Under 30 | 375 (33) | 153 (28) | 19 (7) | ||||
| 30 to 35 | 371 (33) | 206 (38) | 55 (21) | ||||
| Above 35 | 383 (34) | 185 (34) | 188 (72) | ||||
| Tumor burden/activity | |||||||
| Bone marrow plasma cells, % | 14.76 | .005 | |||||
| Under 20 | 290 (25) | 116 (22) | 75 (26) | ||||
| 20 to 50 | 532 (46) | 231 (43) | 107 (38) | ||||
| Above 50 | 326 (28) | 190 (35) | 103 (36) | ||||
| C-reactive protein, mg/L | 3.86 | .14 | |||||
| 10 or less | 455 (67) | 214 (64) | 118 (60) | ||||
| Above 10 | 220 (33) | 121 (36) | 78 (40) | ||||
| Serum β-2 microglobulin, mg/L | 76.38 | < .001 | |||||
| 4 or less | 431 (29) | 171 (24) | 63 (18) | ||||
| 4 to 8 | 608 (41) | 291 (42) | 98 (28) | ||||
| Above8 | 438 (30) | 237 (34) | 188 (54) | ||||
| Hemopoietic function | |||||||
| Anemia, Hb g/dL | 12.64 | .01 | |||||
| Less than 7.5 | 138 (10) | 84 (13) | 50 (15) | ||||
| 7.5 to 10 | 467 (33) | 242 (36) | 100 (30) | ||||
| Above 10 | 797 (57) | 344 (51) | 184 (55) | ||||
| Thrombocytopenia, platelets × 109/L | 17.67 | .001 | |||||
| Less than 80 | 24 (2) | 18 (3) | 11 (4) | ||||
| 80 to 150 | 141 (11) | 103 (16) | 44 (14) | ||||
| Above 150 | 1169 (88) | 521 (81) | 256 (82) | ||||
| Neutrophils, × 109/L | 25.73 | < .001 | |||||
| Less than 1.8 | 81 (6) | 45 (7) | 11 (3) | ||||
| 1.8 to 3 | 384 (29) | 204 (32) | 61 (19) | ||||
| Above 3 | 851 (65) | 390 (61) | 245 (77) | ||||
| Skeletal disease | |||||||
| Corrected calcium, μM | 51.55 | < .001 | |||||
| 2.63 or less | 812 (72) | 296 (55) | 177 (69) | ||||
| Above 2.63 | 311 (28) | 245 (45) | 80 (31) | ||||
| Bone pain | 1.99 | .74 | |||||
| Present | 512 (34) | 259 (36) | 131 (36) | ||||
| Absent | 174 (12) | 75 (10) | 36 (10) | ||||
| No information | 827 (55) | 384 (53) | 194 (54) | ||||
| Fractures | 6.54 | .16 | |||||
| Present | 468 (31) | 214 (30) | 125 (35) | ||||
| Absent | 587 (39) | 261 (36) | 120 (33) | ||||
| No information | 458 (30) | 243 (34) | 116 (32) | ||||
| Lytic lesions | 45.23 | < .001 | |||||
| None | 382 (25) | 166 (23) | 36 (10) | ||||
| Isolated | 100 (7) | 43 (6) | 22 (6) | ||||
| Multiple | 867 (57) | 421 (59) | 266 (74) | ||||
| No information | 164 (11) | 88 (12) | 37 (10) | ||||
| Serum phosphate, μM | 7.90 | .10 | |||||
| Less than 0.99 | 66 (18) | 30 (17) | 13 (15) | ||||
| 0.99 to 1.5 | 233 (64) | 117 (67) | 50 (56) | ||||
| Above 1.5 | 63 (17) | 28 (16) | 26 (29) | ||||
| Renal disease | |||||||
| Serum creatinine, μM | 170.52 | < .001 | |||||
| Less than 130 | 936 (64) | 436 (62) | 128 (36) | ||||
| 130 to 199 | 330 (23) | 151 (22) | 81 (23) | ||||
| Above 199 | 193 (13) | 113 (16) | 149 (42) | ||||
| Blood urea, μM | 98.17 | < .001 | |||||
| Less than 6.5 | 760 (51) | 363 (51) | 122 (34) | ||||
| 6.5 to 10 | 454 (30) | 195 (28) | 85 (24) | ||||
| Above 10 | 280 (19) | 150 (21) | 154 (43) | ||||
. | Paraprotein class, no. (%) . | . | . | . | . | ||
|---|---|---|---|---|---|---|---|
| Factor and grouping . | IgG . | IgA . | LCO . | χ2 . | P . | ||
| General characteristics | |||||||
| Sex | 4.52 | .15 | |||||
| Male | 880 (58) | 413 (58) | 188 (52) | ||||
| Female | 632 (42) | 305 (42) | 173 (48) | ||||
| Age, y | 16.88 | .001 | |||||
| Under 65 | 744 (49) | 334 (47) | 215 (60) | ||||
| 65 or more | 767 (51) | 383 (53) | 146 (40) | ||||
| Performance status | 26.68 | .001 | |||||
| Asymptomatic | 193 (14) | 69 (10) | 19 (6) | ||||
| Minimal symptoms | 516 (37) | 257 (38) | 111 (33) | ||||
| Restricted activity | 544 (39) | 273 (41) | 166 (49) | ||||
| Bedridden | 151 (11) | 69 (10) | 41 (12) | ||||
| Serum albumin, g/L | 149.03 | < .001 | |||||
| Under 30 | 375 (33) | 153 (28) | 19 (7) | ||||
| 30 to 35 | 371 (33) | 206 (38) | 55 (21) | ||||
| Above 35 | 383 (34) | 185 (34) | 188 (72) | ||||
| Tumor burden/activity | |||||||
| Bone marrow plasma cells, % | 14.76 | .005 | |||||
| Under 20 | 290 (25) | 116 (22) | 75 (26) | ||||
| 20 to 50 | 532 (46) | 231 (43) | 107 (38) | ||||
| Above 50 | 326 (28) | 190 (35) | 103 (36) | ||||
| C-reactive protein, mg/L | 3.86 | .14 | |||||
| 10 or less | 455 (67) | 214 (64) | 118 (60) | ||||
| Above 10 | 220 (33) | 121 (36) | 78 (40) | ||||
| Serum β-2 microglobulin, mg/L | 76.38 | < .001 | |||||
| 4 or less | 431 (29) | 171 (24) | 63 (18) | ||||
| 4 to 8 | 608 (41) | 291 (42) | 98 (28) | ||||
| Above8 | 438 (30) | 237 (34) | 188 (54) | ||||
| Hemopoietic function | |||||||
| Anemia, Hb g/dL | 12.64 | .01 | |||||
| Less than 7.5 | 138 (10) | 84 (13) | 50 (15) | ||||
| 7.5 to 10 | 467 (33) | 242 (36) | 100 (30) | ||||
| Above 10 | 797 (57) | 344 (51) | 184 (55) | ||||
| Thrombocytopenia, platelets × 109/L | 17.67 | .001 | |||||
| Less than 80 | 24 (2) | 18 (3) | 11 (4) | ||||
| 80 to 150 | 141 (11) | 103 (16) | 44 (14) | ||||
| Above 150 | 1169 (88) | 521 (81) | 256 (82) | ||||
| Neutrophils, × 109/L | 25.73 | < .001 | |||||
| Less than 1.8 | 81 (6) | 45 (7) | 11 (3) | ||||
| 1.8 to 3 | 384 (29) | 204 (32) | 61 (19) | ||||
| Above 3 | 851 (65) | 390 (61) | 245 (77) | ||||
| Skeletal disease | |||||||
| Corrected calcium, μM | 51.55 | < .001 | |||||
| 2.63 or less | 812 (72) | 296 (55) | 177 (69) | ||||
| Above 2.63 | 311 (28) | 245 (45) | 80 (31) | ||||
| Bone pain | 1.99 | .74 | |||||
| Present | 512 (34) | 259 (36) | 131 (36) | ||||
| Absent | 174 (12) | 75 (10) | 36 (10) | ||||
| No information | 827 (55) | 384 (53) | 194 (54) | ||||
| Fractures | 6.54 | .16 | |||||
| Present | 468 (31) | 214 (30) | 125 (35) | ||||
| Absent | 587 (39) | 261 (36) | 120 (33) | ||||
| No information | 458 (30) | 243 (34) | 116 (32) | ||||
| Lytic lesions | 45.23 | < .001 | |||||
| None | 382 (25) | 166 (23) | 36 (10) | ||||
| Isolated | 100 (7) | 43 (6) | 22 (6) | ||||
| Multiple | 867 (57) | 421 (59) | 266 (74) | ||||
| No information | 164 (11) | 88 (12) | 37 (10) | ||||
| Serum phosphate, μM | 7.90 | .10 | |||||
| Less than 0.99 | 66 (18) | 30 (17) | 13 (15) | ||||
| 0.99 to 1.5 | 233 (64) | 117 (67) | 50 (56) | ||||
| Above 1.5 | 63 (17) | 28 (16) | 26 (29) | ||||
| Renal disease | |||||||
| Serum creatinine, μM | 170.52 | < .001 | |||||
| Less than 130 | 936 (64) | 436 (62) | 128 (36) | ||||
| 130 to 199 | 330 (23) | 151 (22) | 81 (23) | ||||
| Above 199 | 193 (13) | 113 (16) | 149 (42) | ||||
| Blood urea, μM | 98.17 | < .001 | |||||
| Less than 6.5 | 760 (51) | 363 (51) | 122 (34) | ||||
| 6.5 to 10 | 454 (30) | 195 (28) | 85 (24) | ||||
| Above 10 | 280 (19) | 150 (21) | 154 (43) | ||||